Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)
China · Delayed Price · Currency is CNY 22.90
-1.16 (-4.82%)
At close: Nov 6, 2026
SHA:688806 Revenue
Zhuhai Trinomab Pharmaceutical had revenue of 78.32M CNY in the quarter ending September 30, 2026, with 655.28% growth. This brings the company's total for the last twelve months to 175.37M. In the year 2025, Zhuhai Trinomab Pharmaceutical had annual revenue of 51.22M with 240.23% growth. That makes Zhuhai Trinomab Pharmaceutical the 32,226th largest company in the world by revenue and 5,034th in China.
Revenue (ttm)
175.37M
Revenue Growth
+240.23%
P/S Ratio
60.14
Revenue / Employee
200.19K
Employees
876
Market Cap
10.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.22M | 36.17M | 240.23% |
| Dec 31, 2024 | 15.06M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 4.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.